Auralys Therapeutics is pleased to announce the appointment of Dr. Laila Monroe, M.D., as Chief Medical Officer (CMO), bringing more than two decades of clinical development leadership to the company’s rapidly advancing therapeutic pipeline.
Dr. Monroe joins Auralys from her most recent role as Senior Vice President of Clinical Development at a leading global biotech firm, where she oversaw the clinical strategy and execution for several breakthrough oncology and immunology programs. With a track record of guiding novel drug candidates from first-in-human studies through late-stage development and regulatory approval, she brings unmatched expertise in translating scientific innovation into patient impact.
“Dr. Monroe’s appointment marks a pivotal moment for Auralys as we transition from preclinical innovation to clinical execution,” said [CEO Name], Chief Executive Officer of Auralys Therapeutics. “Her deep clinical insights, regulatory expertise, and passion for patient-centric innovation align perfectly with our mission to deliver transformative medicines.”
In her role as CMO, Dr. Monroe will lead:
- Clinical strategy for Auralys’ lead candidates, including AUR-101 and AUR-202
- Design and oversight of Phase 1 and 2 clinical trials across oncology, neurology, and immunology indications
- Regulatory strategy and engagement with global health authorities
- Medical affairs and scientific communication initiatives
“I’m thrilled to join Auralys at such an exciting stage,” said Dr. Monroe. “The team’s integrated approach—combining cutting-edge AI technologies with deep biological science—is exactly what the future of medicine requires. I’m eager to help shape the clinical development programs that will bring these promising therapies to patients.”
Dr. Monroe’s Background:
- M.D., University of California, San Francisco
- Former roles at Genentech, Bristol Myers Squibb, and two successful biotech exits
- Clinical lead on more than 15 Phase 1–3 programs in oncology, rare disease, and autoimmunity
- Known for pioneering adaptive trial designs and patient-centric protocols
With Dr. Monroe’s addition, Auralys strengthens its leadership team at a critical inflection point, as its lead programs approach IND submission and clinical trial readiness. Her appointment reflects the company’s ongoing commitment to excellence, strategic growth, and patient-focused innovation.
For press inquiries or more information about our leadership and pipeline, please contact info@auralysbiotech.com.